(UPDATE 12/19) FDA Drug Safety Communication: Multaq (dronedarone)
The U.S. Food and Drug Administration (FDA) is reviewing data from a clinical trial that was evaluating the effects of the antiarrhythmic drug Multaq ( dronedarone ) in patients with permanent atrial fibrillation.
